For this review, I looked for weak and oversold market averages on monthly charts by using one of my favorite technical indicators��SI (Relative Strength Index)��o identify what may be promising buy areas from which rallies could develop, explains Bonnie Gortler in Systems and Forecasts.
Although it was not an easy task to find market averages that are oversold on a long-term basis, because the stock market has been trending higher since 2009, I found four out-of-favor ETFs that intrigued me and could be good investment opportunities in 2014.
The iShares Silver Trust ETF (SLV), which tracks silver bullion, peaked in April 2011 at $48.35. A rally attempt, from the lows in June 2012, failed in September 2012, and was unable to gather much momentum to the upside until July of 2013. Once again, the rally failed.
SLV is best for aggressive traders, not for conservative investors, because it is very volatile. Aggressive traders could buy now if they want to take a chance that the bottom is in and don't want to wait until the downtrend is broken. I do suggest a tight stop of 5% below your purchase, just in case the final bottom is not in.
10 Best Energy Stocks To Invest In 2015: Rent-A-Center Inc.(RCII)
Rent-A-Center, Inc., together with its subsidiaries, primarily engages in leasing household durable goods to customers on a rent-to-own basis. The company?s stores offer durable products, such as consumer electronics, appliances, computers, and furniture and accessories under flexible rental purchase agreements that allow the customer to obtain ownership of the merchandise at the conclusion of an agreed upon rental period. It also provides merchandise on an installment sales basis in its stores. As of December 31, 2010, the company operated 3,008 company-owned stores in the United States, and in Canada, Puerto Rico, and Mexico, including 42 retail installment sales stores under the names ?Get It Now? and ?Home Choice?; and 18 rent-to-own stores located in Canada under the ?Rent-A-Centre? name. It also operates 209 franchised rent-to-own stores in 32 states under the ColorTyme trade name; and 384 kiosk locations under the ?RAC Acceptance? model. In addition, the company, th rough its ColorTyme?s franchised stores, offers custom rims and tires for sale or rental under the trade names ?RimTyme? or ?ColorTyme Custom Wheels?. Rent-A-Center, Inc. was founded in 1986 and is headquartered in Plano, Texas.
Advisors' Opinion:- [By Garrett Cook]
Rent-A-Center (NASDAQ: RCII) shares tumbled 12.42 percent to $25.45 after the company issued a downbeat guidance for the second quarter. The company expected adjusted earnings of $0.36 to $0.38 per share on revenue of around $773 million.
Top Promising Companies To Buy For 2014: Primo Water Corporation(PRMW)
Primo Water Corporation, together with its subsidiaries, provides three- and five-gallon purified bottled water, self-serve filtered drinking water, water dispensers, and carbonating beverage appliances in the United States and Canada. The company?s Primo Water segment sells multi-gallon purified bottled water and self-serve filtered drinking water vending service through retailers in the United States and Canada. It offers its services through point of purchase display racks or self-serve filtered water vending displays, and recycling centers. Its Primo Dispensers segment sells water dispensers that are designed to dispense Primo and other dispenser-compatible bottled water. This segment engages in dispensers sales primarily through retailers. The company also offers home beverage appliances, flavor concentrates, carbon dioxide cylinders, and accessories used with the appliances to make various cold beverages. As of December 31, 2011, its exchange and refill services wer e offered in each of the contiguous United States and in Canada at approximately 23,600 combined retail locations. Primo Water Corporation was founded in 2004 and is headquartered in Winston-Salem, North Carolina.
Advisors' Opinion:- [By Bryan Murphy]
In November of last year when I first started to suggest Primo Water Corporation (NASDAQ:PRMW) was un undervalued and underappreciated investment opportunity, I received plenty of, shall we call them "colorful disagreements"? PRMW was still sitting in the shadow of a 95% selloff (for a couple of different reasons), and nobody seemed to the think the company was going to survive. I saw hope though, making me the outlier. Glad I was able to look past all the noise and bearish rhetoric and stay convicted to my idea - Primo Water shares are up 146% since my initial call. You know what though, in the same sense I was willing to zig then when everyone else had zagged, I think it's time to close the books on this then-unlikely winner. More on that in a second.
- [By John Udovich]
Small cap water stocks Primo Water Corporation (NASDAQ: PRMW), Arrowhead Water Products Ltd. (CVE: AWA) and Alkaline Water Company Inc (OTCBB: WTER) might be the last place you expect to see much action, but these stocks have been boiling lately for investors���either with news or they have been producing profits:
- [By James E. Brumley]
The initial thought may be that it's a bit of an awkward sales venue. The more one thinks about it - and digs - the more this relationship makes sense. And if you did really deep into the details (into a philosophical level), a "whole is greater than the sum of its parts" scenario surfaces. What's this not-really-unusual relationship? The Alkaline Water Company Inc. (OTCBB:WTER) is now selling its Alkaline88 brand of water through Amazon.com, Inc. (NASDAQ:AMZN). Take that Primo Water Corporation (NASDAQ:PRMW)!
- [By Bryan Murphy]
Look out Primo Water Corporation (NASDAQ:PRMW), there's a serious threat nipping out your heels, and there way of "doing bottled water" may be a heck of a lot easier for consumers to swallow than your way. The name of that budding competition? Alkaline Water Company Inc. (OTCBB:WTER). In fact, WTER became just a little more competitive on Tuesday thanks to widening its reach.... again.
Top Promising Companies To Buy For 2014: Epizyme Inc (EPZM)
Epizyme, Inc., incorporated on November 1, 2007, is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. The Company systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of its product candidates is directed towards patients with a particular genetically defined cancer.The Company is conducting a Phase I clinical trial of its advanced product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT, for the treatment of mixed lineage leukemia (MLL-r). The Company has identified its two lead product candidates using its product platform.
EPZ-5676-DOT1L Inhibitor
EPZ-5676 is an intravenously administered small molecule inhibitor of DOT1L. The Company is developing EPZ-5676 for the treatment of MLL-r, an aggressive subtype of the two most common forms of acute leukemia, ALL and AML. Patients with MLL-r are routinely diagnosed with existing technologies that are commonly used in clinical setting. The Company�� Phase 1 clinical trial of EPZ-5676 is an open label, multicenter trial that has two phases.
EPZ-6438-EZH2 Inhibitor
The Company is developing EPZ-6438 as an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients who have an oncogenic point mutation in EZH2. EZH2 is an HMT that can become oncogenic and cause non-Hodgkin lymphoma and a range of other solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are particularly associated with an EZH2 point mutation. There are no therapies approved specifically for the treatment of cancer associated with an EZH2 point mutation.
Advisors' Opinion:- [By Lisa Levin]
Epizyme (NASDAQ: EPZM) shares rose 66.84% to $34.20. The volume of Epizyme shares traded was 1683% higher than normal. Epizyme reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.
- [By John Udovich]
It�� a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or�pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for�Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ:�RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:
Top Promising Companies To Buy For 2014: Datawatch Corporation(DWCH)
Datawatch Corporation engages in the design, development, manufacture, marketing, and support of business computer software products primarily in the United States and the United Kingdom. The company?s products include Monarch 11, a desktop reporting and data analysis application that allows users to extract and manipulate data from ASCII report files, PDF files, or HTML files; Monarch Data Pump, a data replication and migration tool, which provides information delivery and data extract, and transform and load capabilities in one automated solution; and Monarch Enterprise Server that offers Web-enabled report storage, transformation, and distribution, including data analysis, visualization, and MS Excel integration. It also offers Monarch RMS, a Web-based report analytics solution that integrates with existing enterprise content management system; Monarch Report Manager on Demand, a document archive system that stores text, images, intelligent data streams, and unstructur ed content with file compression and encryption; and Datawatch Dashboards, an interactive dashboard solution that gives various levels of users a visual overview of operational performance, as well as the ability to monitor specific business processes and events. In addition, the company provides iMergence iStore, a report management solution, which manages computer-generated reports, mines the data contained in them, and allows users to interactively merge and transform them into new reports; Visual QSM, a Web-enabled IT service management system that incorporates workflow and network management capabilities, and provides Web access to multiple databases while enabling customers to interact through browser; and Visual Help Desk, which offers Web-based help desk and call center solutions. It sells its products through direct sales force, value added resellers, and distributors. Datawatch Corporation was founded in 1985 and is headquartered in Chelmsford, Massachusetts.
Advisors' Opinion:- [By Sean Williams]
A clouded future
With cost-cutting and operational efficiency being the name of the game for most tech companies in this uncertain growth environment, companies like Datawatch (NASDAQ: DWCH ) , which provides information optimization for enterprise networks, are thriving. - [By James Oberweis]
Steve Halpern: We're conducting a series of interviews with the top performing advisors from last year's Top Picks Report. This past year, your top stock pick, Datawatch (DWCH) rose more than 150%. Congratulations on that.
Top Promising Companies To Buy For 2014: Sucampo Pharmaceuticals Inc (SCMP)
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�� prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�� products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl).
AMITIZA
The Company�� AMITIZA is being marketed in the United States for three gastrointestinal indications under a license agreement, or the Takeda Agreement, with Takeda Pharmaceutical Company Limited, or Takeda. The three gastrointestinal indications include chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. AMITIZA for OIC received approval from the United States Food and Drug Administration (FDA), in April 2013. In Japan, AMITIZA is marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd. (Abbott), for the gastrointestinal indication of chronic constipation (CC), excluding constipation caused by organic diseases. In Switzerland, the Company is marketing AMITIZA.
RESCULA
The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People�� Republic of China. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure (IOP), in patients with open-angle glaucoma or ocular hypertension in the United States. RESCULA may be used as an agent or concomit! antly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 stock that's starting to trend within range of triggering a major breakout trade is Sucampo Pharmaceuticals (SCMP), which is engaged in the discovery, development and commercialization of proprietary drugs based on prostones, and other novel drug technologies. This stock is off to a decent start in 2013, with shares up by 26%.
If you take a look at the chart for Sucampo Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last four months, with shares dumping hard from its high of $10.48 to its recent low of $5.40 a share. During that downtrend, shares of SCMP have been consistently making lower highs and lower lows, which is bearish technical price action. That said, the downside volatility for SCMP looks to be over in the short-term since the stock has started to reverse its downtrend and enter an uptrend. That reverse is quickly pushing shares of SCMP within range of triggering a major breakout trade above a key downtrend line.
Traders should now look for long-biased trades in SCMP if it manages to break out above some near-term overhead resistance levels at $6.33 to $6.66 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 115,383 shares. If that breakout triggers soon, then SCMP will set up to re-test or possibly take out its next major overhead resistance levels at $7.09 to $7.67 a share. Any high-volume move above those levels will then give SCMP a chance to tag $8 to $9 a share.
Traders can look to buy SCMP off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $5.58 to $5.40 a share. One can also buy SCMP off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By James Brumley]
Still, for the nimble who know when to get out, OREX is one of the few cheap stocks worth a closer look.
Sucampo Pharmaceuticals (SCMP)Finally, though the price of $7.60 clearly qualifies it as one pf the cheapest of the cheap stocks out there in the pharmaceutical world, that’s not the reason Sucampo Pharmaceuticals (SCMP) may be worth a look here. It’s the 30% slide we’ve seen SCMP stock suffer since peaking in mid-January. It’s not a pullback that’s bound to go unchallenged by the bulls.
Top Promising Companies To Buy For 2014: Tableau Software Inc (DATA)
Tableau Software, Inc., incorporated on July 19, 2004, is a computer software company. The Company�� products are used by people across all kinds of organizations, including Fortune 500 corporations, small and medium-sized businesses, government agencies, universities, research institutions and non-profits. Organizations employ its products in a range of use cases, such as increasing sales, streamlining operations, improving customer service, managing investments, assessing quality and safety, studying and treating diseases, completing academic research, addressing environmental problems and improving education. The Company�� product helps a single user on a laptop analyze data from a simple spreadsheet, or to enable thousands of users across an enterprise to execute queries against databases.
The Company�� technology includes VizQL and its Hybrid Data Architecture. VizQL, translates drag-and-drop actions into data queries and then expresses that information visually. VizQL unifies the formerly disparate tasks of query and visualization and allows users to transform questions into pictures without the need for software scripts, chart wizards or dialogue boxes that inhibit speed and flexibility. The Company�� Hybrid Data Architecture combines the power and flexibility of its Live Query and In-Memory Data Engines. The Company�� Live Query Engine allows users to instantaneously connect to volumes of data in its existing format and location, reducing the need for time-consuming data transformation processes that only technical specialists can perform. In addition, this capability allows customers to leverage investments in their existing data platforms and to capitalize on the capabilities of high performance databases. The Company�� In-Memory Data Engine enables users to import amounts of data into its own in-memory database.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Tableau Software (NYSE: DATA) shot up 15.54 percent to $91.77 after the company reported upbeat Q4 results. FBN Securities lifted the price target on the stock from $85.00 to $110.00. - [By Tim Beyers]
Tableau Software (NYSE: DATA ) , one of this year's most exciting new IPOs, burst onto the scene with two straight days of surging stock prices. There's much to like about the business of data visualization, so keep an eye on this stock.
No comments:
Post a Comment